LGALS3 (Galectin 3)

Moreover, targeted interventions against distinct immune escape pathways-such as the Ubiquitin-Conjugating Enzyme E2T (UBE2T)/Cell Division Cycle 42 (CDC42)/Cluster of Differentiation 276 (CD276) and C-C Motif Chemokine Ligand 2-C-C Motif Chemokine Receptor 2/C-C Motif Chemokine Receptor 4 (CCL2-CCR2/CCR4) axes-have shown promise in reshaping the immune microenvironment and enhancing the efficacy of conventional immunotherapy. Collectively, this perspective outlines evolving strategies in immune checkpoint modulation, cellular ecosystem reprogramming, and neuroimmune intervention, providing a forward-looking framework to enhance the efficacy of immunotherapy in BCBrM.

These results may be important in terms of obtaining new immunohistochemical clues for diagnosis and carcinogenesis in thyroid PTCs and their metastases. The number of cases in our study is limited, and we think that supporting the results with a large series of studies may contribute to the diagnosis and prognosis of the patients.

Chloroquine is a widely used anti-malarial drug that triggers lysosome membrane permeabilization (LMP) to liberate sequestered drugs from these organelles...This can be achieved on fixed cells by detecting endogenous LGALS3 with immunostaining or by the visualization of a transgenic LGALS3-mCherry fusion protein on live cells. Altogether, these methods facilitate qualitative and quantitative fluorescence imaging of lysosomal sequestration and liberation of lysosomotropic drugs.

Furthermore, it may hold significance in the monitoring of the inflammatory process during the course of the disease. The demonstrated presence of galectins derived from cancer cells in the blood of women with breast cancer provides a basis for further research into their use as potential biomarkers, useful both in diagnosis and monitoring of the course of the disease and also creates opportunities for application in modern targeted therapy.

Notably, faster clearance of [99mTc]MCP in galectin-3 (Gal-3) knockout mice suggests a role for Gal-3 in systemic retention or an indirect contribution to antitumor activity. These findings provide new insights into MCP pharmacological profile, highlight the limitations of oral delivery, and underscore the need for improved delivery strategies to enhance the therapeutic potential of pectin-based cancer treatments.

The logarithm of the sST2 concentrations, both before and after haemodialysis, was an independent mortality risk factor in univariate analysis (respectively: hazard ratio [HR] 3.179, 95% confidence interval [CI] 1.492-6.777, p = 0.0027, and HR 3.011, 95% CI 1.447-6.264, p = 0.0032) and multivariate analysis, which also included age, male gender, and body mass index (respectively: HR 2.776, 95% CI 1.306-5.903, p = 0.0080, and HR 2.496, 95% CI 1.224-5.090, p = 0.012). These results suggest the use of sST2 in clinical practice to identify patients at higher risk of death.

Enforcing ST6GAL1 in CAR-T cells did not weaken tumoricidal activity and significantly improved anti-tumor responses and in vivo persistence. Collectively, this study identifies Gal-3 as a key extrinsic suppressor of CAR-T cell function and establish targeted cell surface α2,6 sialylation as a strategy to enhance CAR-T cell resistance to galectin-rich immunosuppressive microenvironments.

Elevated Galectin-3 levels are associated with thyroid dysfunction in general but do not distinguish between hyperthyroidism and hypothyroidism. Therefore, Galectin-3 may reflect underlying inflammatory or fibrotic activity rather than serve as a differential diagnostic biomarker between thyroid functional states.

Concurrently, IL30 suppresses T cell function by reducing CD25 and HLA-DR expression on CD4⁺ and CD8⁺ T cells, inhibiting their activation and proliferation, decreasing TNF-α and IFN-γ production, and boosting LAG-3 expression, which strongly correlates with IL30 levels in clinical samples. Collectively, these findings identify IL30 as a critical driver of melanoma dissemination and T cell exhaustion, providing a mechanistic link to immune resistance and failure of combination immunotherapies.

These outcomes identify the VTCN1-galectin-3 axis as a pivotal mediator of immune suppression in CRC and highlight the therapeutic promise of targeting this pathway. Our work underscores the potential of VTCN1 inhibitors as part of combined treatment modalities, especially for immunotherapy-resistant CRC.

In conclusion, this study expands the molecular genetic spectrum and histomorphological spectrum of PHE. By integrating our data with a systematic literature review, this study provides a comprehensive overview of the clinicopathological features, immunophenotype, molecular genetics, treatment, and prognosis of PHE, offering valuable insights for accurate diagnosis and understanding of its biological behavior.